Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study

Ruxolitinib has demonstrated efficacy in patients with myelofibrosis (MF). However, substantial number of patients may not respond after 3-6 months of treatment or develop resistance over time. In this phase 2 trial, patients with a current diagnosis of intermediate or high-risk MF who either had an...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	American journal of hematology 2023-10, Vol.98 (10), p.1579-1587
Hauptverfasser:	Zhang, Yi, Zhang, Qike, Liu, Qingchi, Dang, Huibing, Gao, Sujun, Wang, Wei, Zhou, Hu, Chen, Yuqing, Ma, Liangming, Wang, Jishi, Yang, Haiping, Lu, Binhua, Yin, Hewen, Wu, Liqing, Suo, Shanshan, Zhao, Qingwei, Tong, Hongyan, Jin, Jie
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Hematology Hemoglobin Leukocytosis Myelofibrosis Spleen Thrombocytopenia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!